Breaking News Instant updates and real-time market news.

PCRX

Pacira

$35.40

-4.45 (-11.17%)

, HRTX

Heron Therapeutics

$39.55

8.85 (28.83%)

15:42
06/21/18
06/21
15:42
06/21/18
15:42

Pacira's Exparel may face greater threat from Heron drug, says BMO Capital

BMO Capital analyst Gary Nachman said the newly released Phase 2b data for Heron Therapeutics' (HRTX) HTX-011 in post-surgical pain support a "very solid profile" for the drug, which he thinks will eventually likely be a "viable competitor" to Pacira's (PCRX) Exparel. Given the new data, a more cautious long-term outlook for Exparel may be warranted, contends Nachman, who keeps a Market Perform rating on Pacira shares. In late day trading, Heron shares are up 29% to $39.70, while Pacira has fallen 12% to $34.98.

PCRX

Pacira

$35.40

-4.45 (-11.17%)

HRTX

Heron Therapeutics

$39.55

8.85 (28.83%)

  • 21

    Jun

  • 26

    Jun

  • 27

    Jun

PCRX Pacira
$35.40

-4.45 (-11.17%)

06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
05/04/18
JMPS
05/04/18
NO CHANGE
Target $56
JMPS
Outperform
Pacira price target lowered to $56 from $65 at JMP Securities
JMP Securities analyst Donald Ellis noted that Pacira Pharmaceuticals reported Q1 earnings that were in-line with consensus and the company reiterated FY18 Exparel sales guidance. He lowered his price target on Pacira to $56 from $65 to account for his updated peer PEG ratios. Ellis maintains an Outperform rating on Pacira, stating that he believes the combination of the DPS partnership, scrutiny against opioids and recent approvals are contributing to the acceleration in Exparel sales.
05/03/18
HCWC
05/03/18
NO CHANGE
Target $48
HCWC
Buy
Pacira being conservative with no guidance raise, says H.C. Wainwright
Pacira Pharmaceuticals this morning posted solid Q1 Exparel sales of $74M, just ahead of the Street's $73.1M estimate and up over 9% year-on-year, H.C. Wainwright analyst Oren Livnat tells investors in a research note. He found it important that management highlighted strong intra-quarter growth trends with 6% growth in January accelerating to 15% in March. The analyst believes, however, that investors are concerned with no Exparel guidance increase and "confusing potential near-term Exparel reimbursement developments, or lack thereof." Livnat believes management is being conservative with the outlook and reiterates a Buy rating on Pacira with a $48 price target. The stock in midday trading is down 4% to $32.95.
04/23/18
CANT
04/23/18
NO CHANGE
Target $40
CANT
Overweight
Doctor call supports Cantor's positive thesis on Heron Therapeutics
After hosting a conference call with two physicians to better understand how HTX-011 will fit into the post-operative pain market, Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Heron Therapeutics (HRTX) with a $40 price target. Both physicians do not see Pacira Pharmaceuticals' (PCRX) Exparel being used anymore if HTX-011 is approved, Chen tells investors in a research note. The doctors believe that HTX-011 is a better drug that is likely to be priced lower than Exparel, the analyst points out. Chen says the call supports her positive thesis on Heron.
HRTX Heron Therapeutics
$39.55

8.85 (28.83%)

06/21/18
NEED
06/21/18
NO CHANGE
Target $66
NEED
Buy
Heron Therapeutics price target raised to $66 from $42 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $66 after the company announced positive topline results from two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation.
06/21/18
CANT
06/21/18
NO CHANGE
Target $40
CANT
Overweight
Cantor has $59 per share 'bull case scenario' for Heron Therapeutics
Cantor Fitzgerald analyst Louise Chen says the positive data announced this morning by Heron Therapeutics will support the new drug application filing for HTX-011 and expand the commercial opportunity for the drug. The analyst continues to believe that the peak sales potential for HTX-011 is being underappreciated. She has a $40 price target on the shares with a $59 "bull case scenario." Chen keeps an Overweight rating on Heron Therapeutics. The stock in morning trading is up 30% to $39.82.
06/21/18
06/21/18
NO CHANGE
Target $80

Outperform
Heron Therapeutics price target raised to $80 on positive HTX-011 results at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer raised his price target for Heron Therapeutics to $80 from $56 after the company reported data from its two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation. The analyst notes that these were primarily for procuring a broad post-surgical label based on the highly compelling Phase 3 studies of the product in bunionectomy and hernia repair by demonstrating safety and predictable PK. HTX-011 not only demonstrated the required safety and PK profile to support a broad label, but the results showed clear clinical benefit over both placebo and bupivacaine, Schimmer adds. The analyst reiterates an Outperform rating on the shares.
06/21/18
EVER
06/21/18
NO CHANGE
Target $80
EVER
Outperform
Heron Therapeutics price target raised to $80 from $56 at Evercore ISI
Evercore ISI analyst Josh Schimmer raised his price target on Heron Therapeutics to $80 from $56 after the company announced positive topline results from two Phase 2b studies of HTX-011.

TODAY'S FREE FLY STORIES

WSM

Williams-Sonoma

$57.42

1.01 (1.79%)

12:55
03/19/19
03/19
12:55
03/19/19
12:55
Options
Williams Sonoma put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

ZNGA

Zynga

$5.37

0.02 (0.37%)

, AMZN

Amazon.com

$1,782.25

40.25 (2.31%)

12:52
03/19/19
03/19
12:52
03/19/19
12:52
Periodicals
Amazon focuses on building game industry's digital infrastructure, Variety says »

Amazon (AMZN), which owns…

ZNGA

Zynga

$5.37

0.02 (0.37%)

AMZN

Amazon.com

$1,782.25

40.25 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

SPY

SPDR S&P 500 ETF Trust

$283.90

1.44 (0.51%)

, SPX

S&P 500

$0.00

(0.00%)

12:50
03/19/19
03/19
12:50
03/19/19
12:50
Periodicals
Some U.S. officials see China walking back trade offers, Bloomberg reports »

Some U.S. officials are…

SPY

SPDR S&P 500 ETF Trust

$283.90

1.44 (0.51%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$284.09

1.63 (0.58%)

, SPX

S&P 500

$0.00

(0.00%)

12:47
03/19/19
03/19
12:47
03/19/19
12:47
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Some U.S. officials see…

SPY

SPDR S&P 500 ETF Trust

$284.09

1.63 (0.58%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$6.70

0.27 (4.20%)

12:45
03/19/19
03/19
12:45
03/19/19
12:45
Options
SunPower call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$201.50

-4.35 (-2.11%)

12:35
03/19/19
03/19
12:35
03/19/19
12:35
Options
Shopify put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$76.60

-1.23 (-1.58%)

12:32
03/19/19
03/19
12:32
03/19/19
12:32
Hot Stocks
Iberiabank board of directors raises quarterly dividend 5% to 43c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

, MSFT

Microsoft

$117.78

0.18 (0.15%)

12:26
03/19/19
03/19
12:26
03/19/19
12:26
On The Fly
Game On: An exclusive talk with The Voxel Agents' Simon Joslin »

'GARDENS BETWEEN': In an…

NTDOY

Nintendo

$0.00

(0.00%)

MSFT

Microsoft

$117.78

0.18 (0.15%)

SNE

Sony

$46.20

0.105 (0.23%)

FB

Facebook

$163.32

2.86 (1.78%)

TCEHY

Tencent

$0.00

(0.00%)

ATVI

Activision Blizzard

$46.95

1.98 (4.40%)

TTWO

Take-Two

$96.16

2.4 (2.56%)

EA

Electronic Arts

$98.79

-0.9 (-0.90%)

UBSFY

Ubisoft

$0.00

(0.00%)

CCOEY

Capcom

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

PBR

Petrobras

$17.49

0.38 (2.22%)

12:25
03/19/19
03/19
12:25
03/19/19
12:25
Options
Petrobras call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,194.39

10.73 (0.91%)

, GOOGL

Alphabet Class A

$1,198.03

9.94 (0.84%)

12:21
03/19/19
03/19
12:21
03/19/19
12:21
Periodicals
'Cheaper' Google Pixel may be coming, Mashable says »

Citing prior reports…

GOOG

Alphabet

$1,194.39

10.73 (0.91%)

GOOGL

Alphabet Class A

$1,198.03

9.94 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

CPRX

Catalyst Pharmaceuticals

$3.40

0.31 (10.03%)

12:21
03/19/19
03/19
12:21
03/19/19
12:21
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst comments point…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

NVDA

Nvidia

$175.42

6.51 (3.85%)

12:20
03/19/19
03/19
12:20
03/19/19
12:20
Hot Stocks
Nvidia up 4% as executives present at investor day meeting »

Nvidia said during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

BRQS

Borqs Technologies

$4.22

(0.00%)

12:20
03/19/19
03/19
12:20
03/19/19
12:20
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
03/19/19
03/19
12:17
03/19/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
03/19/19
03/19
12:16
03/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRQS

Borqs Technologies

$4.22

(0.00%)

12:15
03/19/19
03/19
12:15
03/19/19
12:15
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
03/19/19
03/19
12:15
03/19/19
12:15
General news
The CNBC Fed survey »

The CNBC Fed survey has…

RCII

Rent-A-Center

$19.91

-1.29 (-6.08%)

12:10
03/19/19
03/19
12:10
03/19/19
12:10
Options
Closing call spread in Rent A Center as shares drop almost 5% »

Closing call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

AAPL

Apple

$187.73

-0.3 (-0.16%)

, DIS

Disney

$113.45

0.38 (0.34%)

12:09
03/19/19
03/19
12:09
03/19/19
12:09
On The Fly
Fly Intel: Wall Street's top stories at midday »

The S&P is rising…

AAPL

Apple

$187.73

-0.3 (-0.16%)

DIS

Disney

$113.45

0.38 (0.34%)

FOX

21st Century Fox

$39.38

-1.47 (-3.60%)

FOXA

21st Century Fox

$40.18

-1.52 (-3.65%)

TFCF

21st Century Fox

$51.25

(0.00%)

EOLS

Evolus

$27.25

3.45 (14.50%)

CPRX

Catalyst Pharmaceuticals

$3.39

0.3 (9.71%)

MIK

Michaels

$13.49

1.7 (14.42%)

DSW

DSW

$21.91

-3.39 (-13.40%)

TACO

Del Taco

$9.81

-0.79 (-7.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 25

    Mar

  • 26

    Mar

  • 11

    Apr

DSW

DSW

$22.01

-3.29 (-13.00%)

, DBI

Designer Brands

$0.00

(0.00%)

12:04
03/19/19
03/19
12:04
03/19/19
12:04
Hot Stocks
DSW announces 3-year strategic priorities, changes name to Designer Brands »

DSW presented the…

DSW

DSW

$22.01

-3.29 (-13.00%)

DBI

Designer Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

MGM

MGM Resorts

$26.89

0.64 (2.44%)

12:04
03/19/19
03/19
12:04
03/19/19
12:04
Hot Stocks
MGM Resorts, Major League Soccer announce multi-year gaming partnership »

MGM Resorts International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ON

ON Semiconductor

$21.99

0.08 (0.37%)

, NVDA

Nvidia

$175.55

6.64 (3.93%)

12:01
03/19/19
03/19
12:01
03/19/19
12:01
Hot Stocks
ON Semiconductor collaborates with Nvidia on cloud-based AV simulation »

ON Semiconductor (ON)…

ON

ON Semiconductor

$21.99

0.08 (0.37%)

NVDA

Nvidia

$175.55

6.64 (3.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

GRUB

GrubHub

$72.12

-4.91 (-6.37%)

12:00
03/19/19
03/19
12:00
03/19/19
12:00
Hot Stocks
GrubHub falls -6.4% »

GrubHub is down -6.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    May

DSW

DSW

$22.06

-3.24 (-12.81%)

12:00
03/19/19
03/19
12:00
03/19/19
12:00
Hot Stocks
DSW falls -13.0% »

DSW is down -13.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

ORN

Orion Group

$3.66

-0.57 (-13.48%)

12:00
03/19/19
03/19
12:00
03/19/19
12:00
Hot Stocks
Orion Group falls -13.7% »

Orion Group is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.